These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19645340)

  • 1. [Novel therapeutics risk management].
    Hagemann U
    Z Evid Fortbild Qual Gesundhwes; 2009; 103(5):269-72. PubMed ID: 19645340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Conference on Harmonisation; guidance on E2E Pharmacovigilance Planning; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Apr; 70(62):16827-8. PubMed ID: 15803631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A call for international harmonization in therapeutic risk management.
    Hirst C; Cook S; Dai W; Perez-Gutthann S; Andrews E
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):839-49; discussion 850-1. PubMed ID: 16981215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systems-based approach to risk management.
    Menighan TE
    J Am Pharm Assoc (2003); 2005; 45(2):116. PubMed ID: 15868747
    [No Abstract]   [Full Text] [Related]  

  • 6. WHO expert committee on specifications for pharmaceutical preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2013; (981):i-xi, 1-188. PubMed ID: 23821930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biocompatibility: the latest developments.
    van Loon J; Mars P
    Med Device Technol; 1997 Dec; 8(10):20-4. PubMed ID: 10184838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologies.
    Tubach F; Lamarque-Garnier V; Castot A;
    Therapie; 2011; 66(4):355-62, 347-54. PubMed ID: 21851800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance assessment of the Thai National Center for Pharmacovigilance.
    Kaewpanukrungsi W; Anantachoti P
    Int J Risk Saf Med; 2015; 27(4):225-37. PubMed ID: 26756896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective risk management programmes.
    Donawa M
    Med Device Technol; 2004 May; 15(4):28-30. PubMed ID: 15303561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bad medicine. Monitoring programs target substandard drugs.
    Grens K
    Mod Healthc; 2013 May; 43(20):30-1. PubMed ID: 23947275
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk management.
    Bartoo G
    IEEE Eng Med Biol Mag; 2003; 22(4):166-70, 172. PubMed ID: 14515712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing the interface with marketing to improve delivery of pharmacovigilance within the pharmaceutical industry.
    Edwards B
    Drug Saf; 2004; 27(8):609-17. PubMed ID: 15154832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Accession to the PIC/S and pharmaceutical quality system in Japan].
    Katori N
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):22-35. PubMed ID: 25707200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality risk management for aseptic processes. Technical report No. 44.
    PDA J Pharm Sci Technol; 2008; 62(1 Suppl TR44):2-39. PubMed ID: 18575382
    [No Abstract]   [Full Text] [Related]  

  • 19. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.